Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial

Cao, Su Mei; Yang, Qi; Guo, Lanwei; Qiang, Hai; Mo, Hao Yuan; Cao, Ke; Qian, Chao Nan; Zhao, Chong; Xiang, Yan; Zhang, Xiu Ping; Lin, Zhi Xiong; Li, Wei Xiong; Liu, Qing; Qiu, Fang; Sun, Rui; Chen, Qiu Yan; Huang, Pei Yu; Luo, Dong Hua; Hua, Yi; Wu, Yu Chun; Lv, Xing; Wang, Lin; Xia, Wei; Ye, Yan Fang; Chen, Ming Yuan; Guo, Xiang; Hong, Ming

doi:10.1016/j.ejca.2016.12.039

Cited by 228 publications

(237 citation statements)

References 32 publications

Supporting

Mentioning

228

Contrasting

Unclassified

Order By: Relevance

“…However, IC did not reduce distant metastasis or prolong survival in previous clinical trials (3)(4)(5)(6)(7). We previously demonstrated that IC plus CCRT increased the distant metastasis-free survival (DMFS) in LA-NPC, but the extent of the improvement was only 4%, with most patients being overtreated (8). It is possible that a better patient stratification can efficiently identify patients at highrisk of metastasis for additional IC.…”

Section: Introductionmentioning

confidence: 93%

A Prognostic Bio-Model Based on SQSTM1 and N-Stage Identifies Nasopharyngeal Carcinoma Patients at High Risk of Metastasis for Additional Induction Chemotherapy

Yang

Zhang

Zou

et al. 2018

Clinical Cancer Research

Self Cite

View full text Add to dashboard Cite

Purpose: Metastasis is one of the most important causes of treatment failure in nasopharyngeal carcinoma (NPC). In T4 or N2-3 patients at high-risk of metastasis, concurrent chemoradiotherapy (CCRT) is inadequate and additional induction chemotherapy (IC) is controversial. There is a critical need to develop a better patient stratification to efficiently identify patients at highrisk of metastasis for additional IC. Recently, Sequestosome 1 (SQSTM1)/p62, an autophagy adaptor protein, was identified as one of the metastasis-related proteins in NPC. However, the mechanism by which SQSTM1 is involved in NPC metastasis was not investigated.Experimental Design: The effect of SQSTM1 on cell migration and invasion was examined in vitro and in vivo. SQSTM1 expression was analyzed in clinical NPC samples using IHC. Luciferase reporter analyses were conducted to identify the effects of SQSTM1 on NF-kB transcriptional activity. A prediction biomodel was constructed by Cox analysis. Retrospective and prospective randomized clinical data were adopted to build and test the model, respectively.Results: SQSTM1 mediated epithelial to mesenchymal transition (EMT) through the NF-kB pathway to promote NPC metastasis. Inhibiting SQSTM1 enhanced sensitivity to cisplatin in NPC cells. In NPC patients, high SQSTM1 expression was associated with increased risk of distant metastasis. Furthermore, we propose a prognostic bio-model based on SQSTM1 and N-stage to predict NPC metastasis. Most importantly, our prospective randomized study suggested that IC is beneficial for NPC patients with high metastasis risk.Conclusions: The prognostic bio-model identifies NPC patients at high-risk of metastasis for additional IC. Clin Cancer Res; 24(3); 648-58. Ó2017 AACR.

show abstract

Section: Introductionmentioning

confidence: 93%

A Prognostic Bio-Model Based on SQSTM1 and N-Stage Identifies Nasopharyngeal Carcinoma Patients at High Risk of Metastasis for Additional Induction Chemotherapy

Yang

Zhang

Zou

et al. 2018

Clinical Cancer Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Neoadjuvant chemotherapy (NAC) followed by intensity‐modulated radiotherapy (IMRT) has currently been widely accepted as an attractive approach in lieu of establishing concurrent chemoradiation therapy (CCRT) in nasopharyngeal carcinoma (NPC) . CCRT is frequently accompanied by acute and late dose‐limiting toxicities, hindering its common use .…”

mentioning

confidence: 99%

Integrating dynamic contrast‐enhanced magnetic resonance imaging and diffusion kurtosis imaging for neoadjuvant chemotherapy assessment of nasopharyngeal carcinoma

Zheng

Lai

Chen

et al. 2018

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…Regarding induction therapy, a phase III trial recently showed that the addition of docetaxel, cisplatin, and fluorouracil prior to CRT was superior to CRT alone in terms of OS and PFS at 3 years, 59 although another trial using cisplatin and fluorouracil as induction therapy failed to show significant differences in OS. 60 The role of induction therapy requires further confirmation from other ongoing phase III trials.…”

Section: Chemotherapymentioning

confidence: 99%

“…62,63 It should be noted, however, that the benefit of more intensive therapy may be limited by the late toxicities of high cumulative doses of chemotherapy, most notably cisplatin, which are not reported in some of the studies. 60,64 Platinum-containing doublet regimens remain the first-line systemic treatment for recurrent or metastatic NPC. Cisplatin and fluorouracil have been the conventional choices.…”

Section: Chemotherapymentioning

confidence: 99%

Beating 'Guangdong cancer': a review and update on nasopharyngeal cancer

2017

Hong Kong Med J

View full text Add to dashboard Cite

Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial

Cited by 228 publications

References 32 publications

A Prognostic Bio-Model Based on SQSTM1 and N-Stage Identifies Nasopharyngeal Carcinoma Patients at High Risk of Metastasis for Additional Induction Chemotherapy

A Prognostic Bio-Model Based on SQSTM1 and N-Stage Identifies Nasopharyngeal Carcinoma Patients at High Risk of Metastasis for Additional Induction Chemotherapy

Integrating dynamic contrast‐enhanced magnetic resonance imaging and diffusion kurtosis imaging for neoadjuvant chemotherapy assessment of nasopharyngeal carcinoma

Beating 'Guangdong cancer': a review and update on nasopharyngeal cancer

Contact Info

Product

Resources

About